RxDoctor Payments DataLook up a doctor →

Seth Rosen, MD

Hematology & Oncology · Port St Lucie, FLNPI 1740398262

Payments from drug & device makers

$5,475,310in general payments, 2019–2025

Across 945 payments — averaging $5793.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$4.4M
  • Array Biopharma Inc$697K
  • Merck$206K
  • Incyte Corporation$127K
  • Genentech, Inc.$2K
  • Johnson & Johnson$852
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alkermes, Inc.267$4,433,357
Array Biopharma Inc57$697,193
Merck28$206,273
Incyte Corporation55$127,133
Genentech, Inc.1$1,500
Johnson & Johnson(2 entities)45$852
Amgen40$835
AstraZeneca(2 entities)37$674
Genentech USA, Inc.48$600
AbbVie(2 entities)30$575
Pfizer48$568
Takeda Pharmaceuticals U.S.A., Inc.16$538
Seagen Inc.23$403
Eisai Inc.18$388
Novartis22$369
Sanofi19$365
E.r. Squibb & Sons, L.L.C.22$320
GSK13$237
Astellas Pharma US Inc10$228
Bayer13$221
Gilead(2 entities)13$212
ASD Specialty Healthcare, LLC2$189
Bristol Myers Squibb9$176
Ipsen Biopharmaceuticals, Inc7$155
Lilly USA, LLC10$151
Daiichi Sankyo Inc.7$134
Boston Scientific1$114
Jazz Pharmaceuticals Inc.6$113
Regeneron Healthcare Solutions, Inc.6$110
Dova Pharmaceuticals5$88
AVEO Pharmaceuticals, Inc.3$84
Exelixis Inc.5$81
AMAG Pharmaceuticals, Inc.5$78
Pharmacyclics LLC, An Abbvie Company4$75
Boehringer Ingelheim5$73
Karyopharm Therapeutics Inc.2$70
Mirati Therapeutics, Inc.3$63
Sobi, Inc3$62
Puma Biotechnology, Inc.3$56
Foundation Medicine, Inc.3$52
Tolmar Pharmaceuticals, Inc.3$50
Tesaro, Inc.3$48
Beone Medicines USA, Inc.2$43
EMD Serono, Inc.2$42
Beigene USA, Inc.2$40
Tolmar, Inc.2$38
Verastem, Inc.2$38
Helsinn Therapeutics (U.S.), Inc.2$28
Rigel Pharmaceuticals, Inc.2$27
Blueprint Medicines Corporation1$25
Taiho Oncology, Inc.1$22
Cumberland Pharmaceuticals, Inc.1$20
Myovant Sciences Inc.1$19
Verity Pharmaceuticals Inc.1$19
Coherus Oncology, Inc.1$19
Accord Healthcare, Inc.1$16
Grifols USA, LLC1$16
Aurobindo Pharma USA, Inc.1$14
Advanced Accelerator Applications1$13
Morphosys, US Inc.1$12

How this compares

$5,475,310 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$4,842,928
Medicare patients
1,148
Services billed
273,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Port St Lucie

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →